Incyclix Bio LLC has received FDA approval of an IND application for INX-315, a novel, potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for advanced or metastatic cancers. The first-in-human phase I/II study will be conducted in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer who have progressed on a CDK4/6 inhibitor regimen and CCNE1-amplified solid tumors that have progressed on standard-of-care treatment.
Adlai Nortye Pharmaceutical Co. Ltd. has identified Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Researchers from the Centro Nacional de Investigaciones Oncológicas aimed to identify pathways that contribute to the metabolic reprogramming ability of cancer cells upon resistance to ataxia-telangiectasia-mutated (ATM) inhibition. Metabolism-centered CRISPR screening identified Kelch-like ECH-associated protein 1 (KEAP1), which is an oxidative stress sensor that controls the Nrf2-regulated antioxidant pathway, as a key factor involved in desensitizing cancer cells to ATM inhibition.
Merit Medical Systems Inc. received a U.S. FDA breakthrough device designation for its Scout MD surgical guidance system, which enables physicians to pinpoint tumor location in soft tissue. The system uses up tiny reflectors to provide multidimensional location data that can improve the ability to remove the entire tumor with minimal trauma to the surrounding tissue, which can be a challenge in surgeries such as lumpectomies.
Jiangsu Hengrui Medicine Co. Ltd., Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have identified antibody-drug conjugates (ADCs) comprising HER2-targeting antibody or antigen-binding fragments linked to eribulin derivatives through a cleavable linker reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has synthesized dual N-(2-aminophenyl)benzamide compounds acting as lysine-specific histone demethylase 1A (LSD1) and histone deacetylase 1 (HDAC1) inhibitors reported to be useful for the treatment of cancer.
Legochem Biosciences Inc. has entered into a license agreement with Elthera AG to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.
